JP2008526876A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526876A5
JP2008526876A5 JP2007550488A JP2007550488A JP2008526876A5 JP 2008526876 A5 JP2008526876 A5 JP 2008526876A5 JP 2007550488 A JP2007550488 A JP 2007550488A JP 2007550488 A JP2007550488 A JP 2007550488A JP 2008526876 A5 JP2008526876 A5 JP 2008526876A5
Authority
JP
Japan
Prior art keywords
composition
irna agent
antisense strand
nucleotides
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526876A (ja
JP5081630B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/000425 external-priority patent/WO2006074346A2/en
Publication of JP2008526876A publication Critical patent/JP2008526876A/ja
Publication of JP2008526876A5 publication Critical patent/JP2008526876A5/ja
Application granted granted Critical
Publication of JP5081630B2 publication Critical patent/JP5081630B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007550488A 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法 Expired - Fee Related JP5081630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64236405P 2005-01-07 2005-01-07
US60/642,364 2005-01-07
US65982805P 2005-03-09 2005-03-09
US60/659,828 2005-03-09
PCT/US2006/000425 WO2006074346A2 (en) 2005-01-07 2006-01-06 RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011220918A Division JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Publications (3)

Publication Number Publication Date
JP2008526876A JP2008526876A (ja) 2008-07-24
JP2008526876A5 true JP2008526876A5 (enExample) 2009-02-19
JP5081630B2 JP5081630B2 (ja) 2012-11-28

Family

ID=36648197

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007550488A Expired - Fee Related JP5081630B2 (ja) 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Country Status (14)

Country Link
US (8) US7507809B2 (enExample)
EP (4) EP2230304B1 (enExample)
JP (3) JP5081630B2 (enExample)
KR (1) KR101169668B1 (enExample)
CN (2) CN101119734B (enExample)
AT (1) ATE551421T1 (enExample)
AU (2) AU2006203934B2 (enExample)
CA (1) CA2594334A1 (enExample)
DK (1) DK2230304T3 (enExample)
EA (3) EA017847B1 (enExample)
ES (1) ES2385811T3 (enExample)
IL (2) IL184162A (enExample)
NZ (1) NZ556097A (enExample)
WO (1) WO2006074346A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US20060089324A1 (en) * 2004-10-22 2006-04-27 Sailen Barik RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CN101119734B (zh) * 2005-01-07 2012-05-09 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
CN103215269B (zh) 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2229459B1 (en) * 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US20120220649A1 (en) * 2009-10-30 2012-08-30 Daiichi Sankyo Company, Limited Modified double-stranded polynucleotide
CA2781290A1 (en) 2009-11-20 2011-05-26 Lynn K. Gordon Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2012027206A1 (en) * 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2872029A1 (en) 2012-05-29 2013-12-05 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
KR20150137350A (ko) * 2014-05-29 2015-12-09 삼성전자주식회사 화상형성장치 및 화상형성장치의 스캔 방법
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN105693557A (zh) * 2016-01-04 2016-06-22 湖北卓熙氟化股份有限公司 一种氟化氢尿素及其制备方法
JP2018012236A (ja) * 2016-07-20 2018-01-25 株式会社東芝 印刷システム
CN108689886B (zh) * 2018-06-22 2021-06-15 湖北卓熙氟化股份有限公司 一种氟化氢尿素的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
HU205839B (en) * 1987-11-18 1992-07-28 Chinoin Gyogyszer Es Vegyeszet Synergetic artropodicide composition containining pirethroides and phosphate-esters as active components
EP0746614A1 (en) * 1994-02-23 1996-12-11 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
AU6848396A (en) * 1995-10-17 1997-05-07 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
EP1007655A1 (en) * 1996-02-15 2000-06-14 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU4425397A (en) * 1996-09-18 1998-04-14 Vanderbilt University Antisense gene therapy for rna viruses
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20060287267A1 (en) * 2001-05-18 2006-12-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030148928A1 (en) 2001-07-20 2003-08-07 Leonid Beigelman Enzymatic nucleic acid peptide conjugates
US6881835B2 (en) 2002-01-04 2005-04-19 Dr. Chip Biotechnology Inc. Detection of respiratory viruses
US20030203356A1 (en) 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
WO2004042002A2 (en) 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2006512906A (ja) * 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
AU2004227414A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals iRNA conjugates
WO2004094345A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Protected monomers
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
TW572579U (en) * 2003-05-12 2004-01-11 Enermax Technology Corp Power supply still capable of dissipating heat after powering off a computer
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
AU2005213485A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Methods and compositions for combination RNAi therapeutics
JP2007531794A (ja) * 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US20060089324A1 (en) * 2004-10-22 2006-04-27 Sailen Barik RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CA2586250A1 (en) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions for treating respiratory viral infections and their use
CN101119734B (zh) 2005-01-07 2012-05-09 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
CA2647728C (en) 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2009055445A2 (en) 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2229459B1 (en) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2010048590A1 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules

Similar Documents

Publication Publication Date Title
EA200900681A1 (ru) Композиция для лечения респираторных синцитиальных вирусов
JP5773535B2 (ja) インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
JP7007304B2 (ja) Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子
JP4718379B2 (ja) 修飾された低分子干渉ｒｎａ分子および使用方法
JP2008283975A5 (enExample)
JP2020094063A5 (enExample)
JP2020533334A (ja) アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
JP2008517940A5 (enExample)
JP2009514877A5 (enExample)
EA200870528A1 (ru) Композиции и способы ингибирования экспрессии гена pcsk9
JP2011511636A5 (enExample)
RU2010139908A (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
TW202120689A (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
CN114846140A (zh) 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
WO2007111998A3 (en) Dsrna compositions and methods for treating hpv infection
JP2008500817A5 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
CN111378656A (zh) 一种抑制埃博拉病毒的核酸、含有该核酸的药物组合物及其用途
EP1945270A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF FACTOR V SUFFER MUTATION GENES
JP2025512771A5 (enExample)
US20050059617A1 (en) Novel anitsense oligonucleotide derivatives against to hepatitis c virus
JPWO2010061881A1 (ja) Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
WO2008109493A4 (en) NUCLEIC ACID COMPOUNDS DESIGNED TO INHIBIT EXPRESSION OF CD19 GENE AND USES THEREOF
WO2008109520A4 (en) Nucleic acid compounds for inhibiting cxc gene expression and uses thereof